vs

Side-by-side financial comparison of Agilent Technologies (A) and Wellgistics Health, Inc. (WGRX). Click either name above to swap in a different company.

Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $1.7M, roughly 1076.2× Wellgistics Health, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs -1667.2%, a 1684.2% gap on every dollar of revenue.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...

Wellgistics Health, Inc. is a U.S.-headquartered healthcare services firm focused on the distribution of prescription pharmaceuticals, over-the-counter medications, and medical supplies. Its key customer segments include retail pharmacies, long-term care facilities, and independent healthcare providers across the domestic market.

A vs WGRX — Head-to-Head

Bigger by revenue
A
A
1076.2× larger
A
$1.8B
$1.7M
WGRX
Higher net margin
A
A
1684.2% more per $
A
17.0%
-1667.2%
WGRX

Income Statement — Q1 2026 vs Q4 2025

Metric
A
A
WGRX
WGRX
Revenue
$1.8B
$1.7M
Net Profit
$305.0M
$-27.9M
Gross Margin
52.6%
-470.2%
Operating Margin
19.6%
-1517.5%
Net Margin
17.0%
-1667.2%
Revenue YoY
7.0%
Net Profit YoY
-4.1%
EPS (diluted)
$1.07
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
A
A
WGRX
WGRX
Q1 26
$1.8B
Q4 25
$1.9B
$1.7M
Q3 25
$1.7B
$3.0M
Q2 25
$1.7B
$7.8M
Q1 25
$1.7B
$10.9M
Q4 24
$1.7B
Q3 24
$1.6B
Q2 24
$1.6B
Net Profit
A
A
WGRX
WGRX
Q1 26
$305.0M
Q4 25
$434.0M
$-27.9M
Q3 25
$336.0M
$-34.3M
Q2 25
$215.0M
$-6.7M
Q1 25
$318.0M
$-32.4M
Q4 24
$351.0M
Q3 24
$282.0M
Q2 24
$308.0M
Gross Margin
A
A
WGRX
WGRX
Q1 26
52.6%
Q4 25
53.2%
-470.2%
Q3 25
51.1%
7.7%
Q2 25
51.9%
6.5%
Q1 25
53.5%
6.4%
Q4 24
53.9%
Q3 24
54.2%
Q2 24
54.4%
Operating Margin
A
A
WGRX
WGRX
Q1 26
19.6%
Q4 25
23.8%
-1517.5%
Q3 25
20.7%
-1047.1%
Q2 25
18.0%
-70.6%
Q1 25
22.4%
-288.6%
Q4 24
24.0%
Q3 24
21.1%
Q2 24
23.1%
Net Margin
A
A
WGRX
WGRX
Q1 26
17.0%
Q4 25
23.3%
-1667.2%
Q3 25
19.3%
-1139.0%
Q2 25
12.9%
-85.6%
Q1 25
18.9%
-298.5%
Q4 24
20.6%
Q3 24
17.9%
Q2 24
19.6%
EPS (diluted)
A
A
WGRX
WGRX
Q1 26
$1.07
Q4 25
$1.53
$-0.24
Q3 25
$1.18
$-0.46
Q2 25
$0.75
$-0.11
Q1 25
$1.11
$-0.62
Q4 24
$1.23
Q3 24
$0.97
Q2 24
$1.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
A
A
WGRX
WGRX
Cash + ST InvestmentsLiquidity on hand
$1.8B
$42.6K
Total DebtLower is stronger
$3.0B
$23.5M
Stockholders' EquityBook value
$6.9B
$-12.4M
Total Assets
$12.8B
$30.5M
Debt / EquityLower = less leverage
0.44×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
A
A
WGRX
WGRX
Q1 26
$1.8B
Q4 25
$1.8B
$42.6K
Q3 25
$1.5B
$4.2M
Q2 25
$1.5B
$419.9K
Q1 25
$1.5B
$2.5M
Q4 24
$1.3B
Q3 24
$1.8B
Q2 24
$1.7B
Total Debt
A
A
WGRX
WGRX
Q1 26
$3.0B
Q4 25
$3.0B
$23.5M
Q3 25
$3.4B
$24.8M
Q2 25
$3.3B
$23.3M
Q1 25
$3.3B
$24.1M
Q4 24
$3.3B
Q3 24
$2.1B
Q2 24
$2.1B
Stockholders' Equity
A
A
WGRX
WGRX
Q1 26
$6.9B
Q4 25
$6.7B
$-12.4M
Q3 25
$6.4B
$6.8M
Q2 25
$6.1B
$905.3K
Q1 25
$6.0B
$4.5M
Q4 24
$5.9B
Q3 24
$5.9B
Q2 24
$6.2B
Total Assets
A
A
WGRX
WGRX
Q1 26
$12.8B
Q4 25
$12.7B
$30.5M
Q3 25
$12.2B
$52.8M
Q2 25
$12.2B
$54.2M
Q1 25
$11.9B
$58.1M
Q4 24
$11.8B
Q3 24
$11.0B
Q2 24
$10.9B
Debt / Equity
A
A
WGRX
WGRX
Q1 26
0.44×
Q4 25
0.45×
Q3 25
0.53×
3.66×
Q2 25
0.55×
25.72×
Q1 25
0.56×
5.39×
Q4 24
0.57×
Q3 24
0.36×
Q2 24
0.34×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
A
A
WGRX
WGRX
Operating Cash FlowLast quarter
$268.0M
$-6.3M
Free Cash FlowOCF − Capex
$175.0M
FCF MarginFCF / Revenue
9.7%
Capex IntensityCapex / Revenue
5.2%
Cash ConversionOCF / Net Profit
0.88×
TTM Free Cash FlowTrailing 4 quarters
$993.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
A
A
WGRX
WGRX
Q1 26
$268.0M
Q4 25
$545.0M
$-6.3M
Q3 25
$362.0M
$-1.1M
Q2 25
$221.0M
$-2.1M
Q1 25
$431.0M
$-1.3M
Q4 24
$481.0M
Q3 24
$452.0M
Q2 24
$333.0M
Free Cash Flow
A
A
WGRX
WGRX
Q1 26
$175.0M
Q4 25
$452.0M
Q3 25
$259.0M
Q2 25
$107.0M
Q1 25
$334.0M
Q4 24
$388.0M
Q3 24
$360.0M
Q2 24
$230.0M
FCF Margin
A
A
WGRX
WGRX
Q1 26
9.7%
Q4 25
24.3%
Q3 25
14.9%
Q2 25
6.4%
Q1 25
19.9%
Q4 24
22.8%
Q3 24
22.8%
Q2 24
14.6%
Capex Intensity
A
A
WGRX
WGRX
Q1 26
5.2%
Q4 25
5.0%
Q3 25
5.9%
Q2 25
6.8%
Q1 25
5.8%
Q4 24
5.5%
Q3 24
5.8%
Q2 24
6.5%
Cash Conversion
A
A
WGRX
WGRX
Q1 26
0.88×
Q4 25
1.26×
Q3 25
1.08×
Q2 25
1.03×
Q1 25
1.36×
Q4 24
1.37×
Q3 24
1.60×
Q2 24
1.08×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

A
A

Service Other$525.0M29%
Chemicaland Energy Market$422.0M23%
Agilent Cross Lab$273.0M15%
Environmentaland Forensics Market$177.0M10%
Food Market$166.0M9%
Academiaand Government Market$130.0M7%
Applied Markets$98.0M5%

WGRX
WGRX

Segment breakdown not available.

Related Comparisons